News & Press Releases

Law360 recently highlighted commentary from ITC Practice Co-chair Robert Vlasis in an article examining the rise in Section 337 investigations involving patents and other IP being litigated at the US International Trade Commission for the first time. The piece outlines several developments that may be contributing to this trend, including the Federal Circuit’s Lashify decision and recent USPTO procedural changes affecting PTAB challenges.

Mintz represented Synnovation Therapeutics LLC, a clinical-stage biotechnology company with a diverse pipeline of novel small-molecule targeted therapies in oncology and immunology, in connection with its definitive agreement with Novartis to acquire Synnovation’s wholly-owned subsidiary, Pikavation Therapeutics Inc., and its portfolio of pan mutant selective PI3Kα inhibitor programs, including its lead clinical asset SNV4818.  

Mintz advised the underwriters in connection with SAB Biotherapeutics’ $85 million public offering.

Member Jacob Hupart was quoted in a Responsible Investor article about a lawsuit challenging the SEC’s pullback from its long standing “no action” review process for shareholder proposals. In the article, Jacob addresses the legal hurdles facing the plaintiffs as they seek to frame the SEC’s policy shift as actionable under the Administrative Procedure Act.

Mintz represented Sixth Street in connection with a $1.3 billion financing – alongside co-investor Blackstone Credit & Insurance – in support of the combination of Paratek Pharmaceuticals (Paratek) and Radius Health (Radius), creating a scaled, multi‑product specialty pharmaceutical company backed by B‑FLEXION Life Sciences.  

Mintz represented Swarmer, Inc (Nasdaq: SWMR), a defense technology company specializing in drone autonomy software, in its initial public offering on the Nasdaq Capital Market.